IRICoR – Institute for Research in Immunology and Cancer – Commercialization of Research, the IRIC/Université de Montréal-based Canadian cancer drug discovery and commercialization cluster, is very pleased to announce the appointment as of today of Mrs. Violetta Dimitriadou as Vice-President, Scientific Operations and new member of IRICoR’s Management team. In this role, Mrs. Dimitriadou’s responsibilities will include developing the operational plan and the strategic objectives to support R&D initiatives, planning and implementing a balanced portfolio strategy, assessing the scientific and commercial potential of drug discovery projects and making investment recommendations.
With more than 25 years of experience in various Canadian biotechnology companies, she provides IRICoR with extensive knowledge of drug development in the private sector.
Mrs. Dimitriadou holds a Ph.D. in Neurosciences/Cytology from l’Université Pierre et Marie Curie (Paris, France) and completed a two-year fellowship at Tufts University (Boston, MA) in the Neuropharmacology Department. She is associated with over 100 scientific publications and presentations.
In charge of various research programs, she also oversaw the pre-clinical and clinical development of new chemical entities with organizations such as GLyPharma Therapeutic, Painceptor Pharma Corp. and Ecopia Biosciences.
“I am particularly excited to welcome Violetta in our team. Her extended expertise in drug discovery most notably in biopharmaceutical companies is an important additional asset for IRICoR’s current and future endeavors. She will be key in our mission to accelerate the discovery of innovative therapies from the best scientific projects from across Canada and abroad”, commented Nadine Beauger, Chief Executive Officer at IRICoR.
The expertise that she has acquired over the course of her various functions is an asset for carrying out the mandates that she will be entrusted with.